drugset
drugset / Trial / NCT00296517

Study In Patients With Depression Not Responding to Selective Serotonin Re-uptake Inhibitors

NCT00296517 ↗

Phase 3 Completed 325 enrolled GlaxoSmithKline
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is designed to evaluate the efficacy and safety in depressive patients who did not respond sufficiently to selective serotonin re-uptake inhibitors (SSRI).

Timeline

Start
2006-01-19
Primary completion
2008-03-28
Completion
2008-03-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 300 mg —

Indications

depressive disorder